| Name | Levonorgestrel |
| Description | Levonorgestrel (D-Norgestrel) is a Progestin and Progestin-containing Intrauterine Device. The physiologic effect of levonorgestrel is by means of Inhibit Ovum Fertilization. |
| In vitro | Levonorgestrel significantly upregulates mRNA expression of the gene encoding luteinizing hormone beta subunit (lhβ) in both male and female cockroaches, while downregulating mRNA expression of the gene encoding follicle-stimulating hormone beta subunit (fshβ). Furthermore, in long-clawed ground squirrels, Levonorgestrel decreases the mRNA expression of ovarian follicle-stimulating hormone receptor, luteinizing hormone receptor, ovarian estrogen receptor β, and progesterone receptor, as well as the mRNA expression of ERα and PR in the uterus. |
| In vivo | Levonorgestrel elevates cyclic AMP levels in the veins and inhibits the activation of protein kinase C induced by PMA. It suppresses progesterone secretion in rat luteal cells, which is stimulated by oLH, dibutyryl-cAMP, and pregnenolone. Levonorgestrel also inhibits contractions induced by high potassium (K(+)) solutions or PMA in the presence and absence of extracellular calcium (Ca(2+)), effectuating endothelium-dependent relaxation through hindrance of calcium ion ingress and protein kinase C activation. Moreover, while the inhibitory effects of Levonorgestrel on estrogen-induced pituitary weight gain and hyperprolactinemia are attenuated by mifepristone, flunarizine does not block its effects. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : 1.5 mg/mL (4.8 mM), Sonication is recommeded.
DMSO : 16.67 mg/mL (53.35 mM), Sonication is recommended.
|
| Keywords | SRD5A1 | progestogenReceptor | progestogen Receptor | ProgesteroneReceptor | Progesterone Receptor | NR3C3 | Levonorgestrel | Inhibitor | inhibit | EstrogenReceptor | Estrogen Receptor | ER |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Metronidazole | Citric Acid Triammonium | L-Methionine | Sodium butanoate | Dimethyl phthalate | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Endocrinology-Hormone Compound Library | FDA-Approved Drug Library | Orally Active Compound Library | Bitter Compound library | Bioactive Compounds Library Max | Bioactive Lipid Compound Library | NMPA-Approved Drug Library |
United States
